skip to main content

Evaluasi Rasionalitas Penggunaan Antihipertensi Golongan Angiotensin II Receptor Blocker (ARB) pada Pasien Penyakit Ginjal Kronis

Annastasia Gabriella Francie Momuat  -  Program Studi Farmasi, Fakultas Kedokteran, Universitas Diponegoro, Indonesia
*Eva Annisaa'  -  Program Studi Farmasi, Fakultas Kedokteran, Universitas Diponegoro, Indonesia
Received: 20 Jan 2023; Revised: 4 Apr 2023; Accepted: 5 Apr 2023; Available online: 14 Apr 2023; Published: 13 Apr 2023.
Open Access Copyright 2023 Generics: Journal of Research in Pharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Penyakit Ginjal Kronis (PGK) adalah abnormalitas struktur atau fungsi ginjal yang ditandai dengan nilai GFR (Glomerular Filtration Rate) < 60 mL/menit/1,73 m2 selama > 3 bulan. Salah satu faktor risiko dari PGK adalah hipertensi. Golongan antihipertensi yang direkomendasikan pada pasien PGK salah satunya adalah Angiotensin II Receptor Blocker (ARB). Hipertensi dapat memperburuk fungsi ginjal, sebaliknya penurunan fungsi ginjal dapat memperburuk hipertensi. Oleh karena itu, penting untuk mengontrol tekanan darah pasien PGK menggunakan antihipertensi dengan penggunaan yang rasional. Penelitian ini bertujuan untuk mengetahui rasionalitas penggunaan antihipertensi golongan ARB pada pasien PGK di RSUP Dr. Kariadi Semarang tahun 2020. Penelitian ini merupakan penelitian observasional deskriptif dengan pengambilan data secara retrospektif. Sampel yang diteliti adalah 80 pasien PGK yang menggunakan golongan ARB dan dipilih menggunakan metode purposive sampling. Data diperoleh dari rekam medis yang dianalisis rasionalitasnya berdasarkan kriteria tepat indikasi, tepat pasien, tepat obat, dan tepat dosis. Hasil yang diperoleh pada penelitian ini adalah 80 pasien dinyatakan tepat indikasi (100%), 80 pasien dinyatakan tepat pasien (100%), 74 pasien dinyatakan tepat obat (92,5%), dan 80 pasien dinyatakan tepat dosis (100%). Oleh karena itu, rasionalitas penggunaan antihipertensi golongan ARB berdasarkan empat kriteria tersebut sudah cukup baik, yaitu sebesar 92,5%.

Fulltext View|Download
Keywords: retrospektif, observasional deskriptif, purposive sampling

Article Metrics:

  1. Aberg, J. A. et al. (2009) Drug information handbook (17 edition). Lexi-Comp Inc
  2. Alkerwi, A. et al. (2017) ‘Prevalence and related risk factors of chronic kidney disease among adults in Luxembourg: Evidence from the observation of cardiovascular risk factors (ORISCAV-LUX) study’. BMC Nephrology, 18(1), pp. 1–10. doi: 10.1186/s12882-017-0772-6
  3. Ashley, C. and Dunleavy, A. (2018) The Renal Drug Handbook, The Renal Drug Handbook. (5th edition). Boca Raton. doi: 10.1201/9780429460418
  4. Cernes, R., Mashavi, M., and Zimlichman, R. (2011) ‘Differential clinical profile of candesartan compared to other angiotensin receptor blockers’. Vascular Health and Risk Management, 7. doi: 10.2147/vhrm.s22591
  5. Chan, T. C. et al. (2014) ‘Addressing health disparities in chronic kidney disease’. International Journal of Environmental Research and Public Health, 11(12). doi: 10.3390/ijerph111212848
  6. Cheung, A. K. et al. (2011) ‘KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease’. Kidney International, 99(38). doi: 10.1016/j.kint.2020.11.003
  7. Chobanian, A. v et al. (2003) JNC 7: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. doi: 10.1161/01.HYP.0000107251.49515.c2
  8. Clase, C. M. et al. (2020) ‘Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference’. Kidney International., 97(1), pp. 42–61. doi: 10.1016/j.kint.2019.09.018
  9. Departemen Kesehatan Republik Indonesia. (2006) Pharmaceutical care untuk penyakit hipertensi. Jakarta: Departemen Kesehatan Republik Indonesia
  10. Dhondup, T. and Qian, Q. (2015) ‘Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure’. Blood Purification, 43(1-3), pp. 179–188. doi: 10.1159/000452725
  11. Everett, B. and Zajacova, A. (2013) ‘Gender differences in hypertension and hypertension awareness among young adults’. Biodemography Soc Biol, 61(1), pp. 1–17. doi: 10.1080/19485565.2014.929488
  12. Fried, L. F. et al. (2013) ‘Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy’. New England Journal of Medicine, 369(20). doi: 10.1056/nejmoa1303154
  13. James, P. A. et al. (2014) ‘2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee’. JAMA, 311(17), pp. 1809. doi: 10.1001/jama.2013.284427
  14. Kaşkal, M. (2020) ‘Hypersensitivity reaction induced with renin-angiotensin-aldosterone system blocker antihypertensive agents’. Demiroglu Science University Florence Nightingale Journal of Medicine, 6(1). doi: 10.5606/fng.btd.2020.25013
  15. Kementerian Kesehatan Republik Indonesia. (2011) Modul penggunaan obat rasional. Jakarta: Kementerian Kesehatan Republik Indonesia
  16. Kementerian Kesehatan Republik Indonesia. (2018) Laporan Riskesdas 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Republik Indonesia
  17. Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019) ‘Hypertension in CKD: Core Curriculum 2019’. American Journal of Kidney Diseases, 74(1), pp. 120–131. doi: 10.1053/j.ajkd.2018.12.044
  18. Mancia, G. et al. (2019) ‘Two-Drug Combinations as First-Step Antihypertensive Treatment’. Circulation Research, 124(7), 1113–1123. doi: 10.1161/CIRCRESAHA.118.313294
  19. NKF-KDIGO. (2013) ‘KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease.’ Official Journal of the International Society of Nephofrology, 158(11), pp. 825–830. doi: 10.7326/0003-4819-158-11-201306040-00007
  20. Preston, C. L. et al. (2015) Stockley’s Drug Interactions 2015. Somerset: Pharmaceutical Press
  21. Rocco, M. et al. (2015) ‘KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update’. American Journal of Kidney Diseases, 3(4), pp. 752–778. doi: 10.34067/KID.0003122021
  22. Sarnowski, A. et al. (2022) ‘Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management’. International Journal of Nephrology and Renovascular Disease, Dove Medical Press Ltd., pp. 215–228. doi: 10.2147/IJNRD.S326464
  23. Schrauben, S.J., Apple, B.J. and Chang, A. R. (2022) ‘Modifiable Lifestyle Behaviors and CKD Progression: A Narrative Review’. International Journal of Nephrology and Renovascular Disease, Dove Medical Press Ltd. doi: 10.34067/KID.0003122021
  24. Skarzynska, M.B., Król, B. and Czajka, L. (2020) ‘Ototoxicity as a side-effect of drugs: literature review’. Journal of Hearing Science, 10(2), pp. 9–19. doi: 10.17430/jhs.2020.10.2.1
  25. Wang, H. H. et al. (2013) ‘Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease’. Plos One, 8(7). doi: 10.1371/journal.pone.0067140

Last update:

No citation recorded.

Last update:

No citation recorded.